Henry C. Marsh

Henry C. Marsh

Auto-generated profile, based on publicly available information

Henry C. Marsh

Celldex Therapeutics, Inc., Needham, MA, USA

Research Focus & Metrics

Academic Career Length

52Years (1975-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 1990 in Science
Verified
Journal Article
Closed access
PDF file
HWHarlan F. Weisman
Harlan F. Weisman
TBThomas Bartow
Thomas Bartow
MLMichelle K. Leppo
Michelle K. Leppo
HMHenry C. Marsh
Henry C. Marsh
GCGerald R. Carson
Gerald R. Carson
DFDouglas T. Fearon
Douglas T. Fearon
The complement system is an important mediator of the acute inflammatory response, and an effective inhibitor would suppress tissue damage in many autoimmune and inflammatory diseases. Such an inhibitor might be found among the endogenous regulatory proteins of complement that block the enzymes that activate C3 and C5. Of these proteins, complement receptor type 1 (CR1; CD35) has the most inhibitory potential, but its restriction to a few cell types limits its function in vivo. This limitation was overcome by the recombinant, soluble human CR1, sCR1, which lacks the transmembrane and cytoplasmic domains. The sCR1 bivalently bound dimeric forms of its ligands, C3b and methylamine-treated C4 (C4-ma), and promoted their inactivation by factor I. In nanomolar concentrations, sCR1 blocked complement activation in human serum by the two pathways. The sCR1 had complement inhibitory and anti-inflammatory activities in a rat model of reperfusion injury of ischemic myocardium, reducing myocardial infarction size by 44 percent. These findings identify sCR1 as a potential agent for the suppression of complement-dependent tissue injury in autoimmune and inflammatory diseases.

8 April 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
LHLinda Hammerich
Linda Hammerich
TMThomas U. Marron
Thomas U. Marron
RURanjan Upadhyay
Ranjan Upadhyay
JSJudit Svensson-Arvelund
Judit Svensson-Arvelund
MDMaxime Dhainaut
Maxime Dhainaut
JBJoshua D. Brody
Joshua D. Brody

23 July 1999 in Science
Verified
Journal Article
Closed access
PDF file
JHJudy Huang
Judy Huang
LKLouis J. Kim
Louis J. Kim
RMRichard Mealey
Richard Mealey
HMHenry C. Marsh
Henry C. Marsh
YZYuan Zhang
Yuan Zhang
DPDavid J. Pinsky
David J. Pinsky
Glycoprotein adhesion receptors such as selectins contribute to tissue injury in stroke. Ischemic neurons strongly expressed C1q, which may target them for complement-mediated attack or C1qRp-mediated clearance. A hybrid molecule was used to simultaneously inhibit both complement activation and selectin-mediated adhesion. The extracellular domain of soluble complement receptor–1 (sCR1) was sialyl Lewis x glycosylated (sCR1sLe x ) to inhibit complement activation and endothelial-platelet-leukocyte interactions. sCR1 and sCR1sLe x colocalized to ischemic cerebral microvessels and C1q-expressing neurons, inhibited neutrophil and platelet accumulation, and reduced cerebral infarct volumes. Additional benefit was conferred by sialyl Lewis x glycosylation of the unmodified parent sCR1 molecule.

1 September 2000 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
CRCharles W. Rittershaus
Charles W. Rittershaus
DMDavid P. Miller
David P. Miller
LTLawrence J. Thomas
Lawrence J. Thomas
MPMichele D. Picard
Michele D. Picard
CHChristopher M. Honan
Christopher M. Honan
URUna S. Ryan
Una S. Ryan
—Using a vaccine approach, we immunized New Zealand White rabbits with a peptide containing a region of cholesteryl ester transfer protein (CETP) known to be required for neutral lipid transfer function. These rabbits had significantly reduced plasma CETP activity and an altered lipoprotein profile. In a cholesterol-fed rabbit model of atherosclerosis, the fraction of plasma cholesterol in HDL was 42% higher and the fraction of plasma cholesterol in LDL was 24% lower in the CETP-vaccinated group than in the control-vaccinated group. Moreover, the percentage of the aorta surface exhibiting atherosclerotic lesion was 39.6% smaller in the CETP-vaccinated rabbits than in controls. The data reported here demonstrate that CETP activity can be reduced in vivo by vaccination with a peptide derived from CETP and support the concept that inhibition of CETP activity in vivo can be antiatherogenic. In addition, these studies suggest that vaccination against a self-antigen is a viable therapeutic strategy for disease management.

1 February 1994 in Transplantation
Verified
Journal Article
Closed access
SPScott K. Pruitt
Scott K. Pruitt
AKAllan D. Kirk
Allan D. Kirk
RBR Randal Bollinger
R Randal Bollinger
HMHenry C. Marsh
Henry C. Marsh
BCBradley H. Collins
Bradley H. Collins
FSFred Sanfilippo
Fred Sanfilippo
The use of xenografts (Xgs) from distantly related species to relieve the increasing shortage of organs for clinical transplantation is prevented by the occurrence of hyperacute rejection (HAR). This process, in which C activation plays a central role, cannot be inhibited with currently available immunosuppressants. In two clinically relevant xenotransplantation models, this study evaluated the effect of C inhibition using recombinant soluble complement receptor type 1 (sCR1) on HAR. In an ex vivo model in which porcine cardiac Xgs were perfused with human blood, cardiac function ceased within 34 min when the perfusate blood was untreated (n = 3). When the perfusate blood was treated with sCR1 (300 micrograms/ml), cardiac Xg function was maintained for up to 4 hr (n = 3). Immunohistologic examination of these Xgs demonstrated deposition of C3b/iC3b and C3d in Xgs perfused with untreated human blood but only C3d deposition in those Xgs perfused with sCR1-treated human blood. These findings are consistent with the cofactor activity of sCR1 for factor I-mediated degradation of deposited C3b/iC3b to C3d. Treatment with sCR1 also prevented the histopathologic changes of HAR observed when untreated blood was used as the perfusate. In an in vivo pig-to-primate heterotopic cardiac xenotransplantation model, in which porcine Xgs transplanted into untreated cynomolgus monkey recipients underwent HAR in 1 hr or less (n = 3), a single intravenous bolus of sCR1 (15 mg/kg) administered to the recipient immediately before Xg reperfusion markedly inhibited total and alternative pathway serum C activity and prolonged Xg survival to between 48 and 90 hr (n = 5). These studies confirm the important role of C activation in HAR of porcine cardiac Xgs by primates and indicate that sCR1 may be a useful agent for xenotransplantation.

1 April 1977 in Journal of Polymer Science: Polymer Chemistry Edition
Verified
Journal Article
Closed access
PDF file
HYH. Yasuda
H. Yasuda
HMH. C. Marsh
H. C. Marsh
EBE. S. Brandt
E. S. Brandt
CRC. N. Reilley
C. N. Reilley